Study for the enantioselectivity of recently developed chiral stationary phases in the context of the development of fast generic screening strategies

Since the discovery that chirality of molecules can have important implications in the domain of drug development, the concept "Chirality of a drug molecule" has become a hot topic in pharmaceutical industry. The reason is that a given chiral molecule has different stereoforms, enantiomers, which often display a different activity in the human body. Regulatory authorities therefore implied guidelines that clearly state that the development of an enantiopure drug should be preferred, while it also has to be demonstrated that the developed drug is indeed enantiopure. Therefore, the development of chiral separation methods is of utmost importance. However, this kind of method development is often time-consuming and given the fact that a time-is-money culture exists in industry, the department already dedicated much research to the development of generic separation strategies using several techniques such as HPLCand supercritical fluid chromatography. These are strategies that propose a chiral separation method in a relatively limited number of predefined experiments. Earlier, different strategies were defined using several chromatographic techniques (NPLC, RPLC, POSC, SFC) using polysaccharide-based chiral stationary phases (CSP). However, the number of these CSP continues to grow and in the meanwhile new types were commercialized which can possibly perform better than those currently used in the strategies. Therefore this project has as goal to evaluate whether the recently commercialized CSP display acceptable enantioselectivity to be included in one of the generic strategies of one of the earlier studied chromatographic techniques (NPLC, RPLC, POSC, SFC).